Cambridge BioTech gets $40M in Funding, Hiring a Dozen
April 18th, 2011
In a big nod to the potential of personalized medicine therapies, Boston biotech start-up BluePrint Medicines has received $40M in Series A Funding from venture capital firm Third Rock Ventures. The company reports plans to hire a dozen new staff by the end of the year.
The money will be used to “develop personalized treatments based on targeted molecular aberrations of cancer.”
A background in scientific research relevant to BluePrint will likely be a pre-requisite for employment. A great way to get on the inside is to research the background of scientists and investors involved with BluePrint—and reach out for an informational interview.
Source: Mass High Tech
